Latest news with #EdwardsLifesciences
Yahoo
23-05-2025
- Health
- Yahoo
Edwards' study demonstrates value in early aortic stenosis intervention
New research by Edwards Lifesciences has demonstrated that early intervention for severe aortic stenosis (AS) before symptoms develop improves patient outcomes and reduces the economic and resource burden on healthcare systems. Edwards' real-world study of more than 24,000 patients with severe AS demonstrated that prompt intervention resulted in an average of 2.2 fewer days spent in hospitals during patients' treatment, 80% fewer heart failure hospitalisations one year after treatment, and cost reductions of $36,000 per patient at the one-year point. The study results were presented as a late-breaking clinical trial at EuroPCR 2025, taking place in Paris, France, between 20 and 23 May. Larry Wood, Edwards' corporate vice president and transcatheter aortic valve replacement (TAVR) and surgical group president, said: 'We are dedicated to advancing robust evidence to help improve outcomes for patients with severe AS. 'These latest findings underscore the importance of early referral to a heart valve team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals.' It is no surprise that Edwards is shining a light on early AS intervention. The medtech giant recently received approval from the US Food and Drug Administration (FDA) on an indication expansion for its SAPIEN 3 TAVR platform in the treatment of patients with asymptomatic severe AS. The approval was supported by data from Edwards' EARLY TAVR trial (NCT03042104). The results demonstrated that asymptomatic severe AS patients randomised to the company's TAVR experienced superior outcomes versus guideline-recommended clinical surveillance (watchful waiting). At a median follow-up of 3.8 years, the data showed that 26.8% of the 455 patients in the trial's TAVR arm experienced death, stroke or unplanned cardiovascular hospitalisation versus 45.3% of the 446 patients in the clinical surveillance arm. According to GlobalData analysis, the global TAVR market is forecast to reach a valuation of around $13.7bn by 2033, up from $6.16bn in 2023. GlobalData's US Healthcare Facility Invoicing Database indicates that Edwards Lifesciences is currently the TAVR market leader, holding more than a 60% share of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards' SAPIEN, with the data showing that the Evolut system led to significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less haemodynamic structural valve dysfunction than the SAPIEN system. According to GlobalData analysis, the Evolut system could become the preferred option among healthcare professionals for patients with symptomatic severe AS and small aortic annulus categories, as evaluated in the trial. "Edwards' study demonstrates value in early aortic stenosis intervention" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Sign in to access your portfolio
Yahoo
23-05-2025
- Health
- Yahoo
Edwards' study demonstrates value in early aortic stenosis intervention
New research by Edwards Lifesciences has demonstrated that early intervention for severe aortic stenosis (AS) before symptoms develop improves patient outcomes and reduces the economic and resource burden on healthcare systems. Edwards' real-world study of more than 24,000 patients with severe AS demonstrated that prompt intervention resulted in an average of 2.2 fewer days spent in hospitals during patients' treatment, 80% fewer heart failure hospitalisations one year after treatment, and cost reductions of $36,000 per patient at the one-year point. The study results were presented as a late-breaking clinical trial at EuroPCR 2025, taking place in Paris, France, between 20 and 23 May. Larry Wood, Edwards' corporate vice president and transcatheter aortic valve replacement (TAVR) and surgical group president, said: 'We are dedicated to advancing robust evidence to help improve outcomes for patients with severe AS. 'These latest findings underscore the importance of early referral to a heart valve team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals.' It is no surprise that Edwards is shining a light on early AS intervention. The medtech giant recently received approval from the US Food and Drug Administration (FDA) on an indication expansion for its SAPIEN 3 TAVR platform in the treatment of patients with asymptomatic severe AS. The approval was supported by data from Edwards' EARLY TAVR trial (NCT03042104). The results demonstrated that asymptomatic severe AS patients randomised to the company's TAVR experienced superior outcomes versus guideline-recommended clinical surveillance (watchful waiting). At a median follow-up of 3.8 years, the data showed that 26.8% of the 455 patients in the trial's TAVR arm experienced death, stroke or unplanned cardiovascular hospitalisation versus 45.3% of the 446 patients in the clinical surveillance arm. According to GlobalData analysis, the global TAVR market is forecast to reach a valuation of around $13.7bn by 2033, up from $6.16bn in 2023. GlobalData's US Healthcare Facility Invoicing Database indicates that Edwards Lifesciences is currently the TAVR market leader, holding more than a 60% share of the US TAVR market. But change may be afoot. Medtronic recently released two-year results from a clinical trial comparing its Evolut system to Edwards' SAPIEN, with the data showing that the Evolut system led to significantly less bioprosthetic valve dysfunction, five times less prosthetic valve thrombosis, and nine times less haemodynamic structural valve dysfunction than the SAPIEN system. According to GlobalData analysis, the Evolut system could become the preferred option among healthcare professionals for patients with symptomatic severe AS and small aortic annulus categories, as evaluated in the trial. "Edwards' study demonstrates value in early aortic stenosis intervention" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22-05-2025
- Business
- Yahoo
Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick
-- Citi analysts revised their MedTech coverage following a volatile first quarter, with several rating changes and adjustments to target prices. While Q1 management commentary broadly aligned with expectations—quantifying tariff headwinds and outlining mitigation plans—the backdrop changed quickly. A 90-day U.S.–China tariff de-escalation announced on May 12 rendered much of the forward-looking guidance "moot," Citi said. Despite this, Citi sees core MedTech fundamentals as stable, citing continued strength in volumes, pricing, and capital expenditure. Still, stock performance was highly sensitive. "Volatility was steep, somewhat given fundamentals, but also positioning," the analysts noted. The sector now looks ahead to Q2 results for the next key catalyst. In the latest update, Citi downgraded Becton Dickinson and Company (NYSE:BDX) to Neutral from Buy, while upgrading Integer Holdings (NYSE:ITGR) to Buy from Neutral. At the same time, it closed a Negative Catalyst Watch on Haemonetics (NYSE:HAE), maintained a Positive Catalyst Watch on Cooper Companies Inc (NASDAQ:COO), and reiterated Boston Scientific (NYSE:BSX) as a Top Pick. Edwards Lifesciences (NYSE:EW) has also been added to that list, while Insulet (NASDAQ:PODD) was removed. For Cooper, which reports its fiscal Q2 2025 results on May 29, Citi expects foreign exchange (FX) to be a central topic. The outlook is helped by positive signals from competitors and a "healthy" mid-single-digit growth in the consumer segment. Citi models 6.5% year-over-year (y/y) ex-FX growth for CooperVision (CVI) sales and 6.9% for CooperSurgical (CSI) sales. The brokerage maintains a Buy rating and a Positive Catalyst Watch on COO. Tariff-related commentary has rapidly evolved, with most MedTech names initially building tariff costs into 2025 forecasts. But the May 12 development has now shifted the narrative. Citi noted that "existing guidance [is] stale," though companies have reiterated mitigation efforts. GE HealthCare (NASDAQ:GEHC), for instance, suggested a 100 basis point reduction in tariff rates could lift 2025 EPS by $0.40. Citi also opened a short-term positive view on Establishment Labs Holdings Inc (NASDAQ:ESTA) and Tandem Diabetes Care (NASDAQ:TNDM), both rated Neutral. Upcoming events—the former's investor day on June 12 and the latter's appearance at the ADA meeting in late June—are expected to support share prices in the near term. "Generally, stocks trade up into such events, even if it doesn't 'hold' the price appreciation afterwards as positioning normalizes," Citi analysts wrote. As part of its reshuffling, Citi removed Insulet from the Top Pick list after a 25% year-to-date gain and nearly 72% increase over the past year. However, it reiterated a Buy rating and raised the price target to $380 from $320. Edwards Lifesciences was added as a Top Pick on the back of several product and clinical milestones expected over the next 12 to 18 months, including European and U.S. launches for SAPIEN M3 and expanded indications for TAVR. Related articles Citi shuffles MedTech stocks: BDX downgraded, ITGR raised; reiterates top pick Planet Fitness rating raised as it is 'nowhere near maxed out' Canadian National Railway's surge in car velocity signals margin upside - CIBC Sign in to access your portfolio
Yahoo
22-05-2025
- Health
- Yahoo
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
PARIS, May 22, 2025--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outcomes. Prompt intervention for severe AS patients before symptoms developed resulted in: Significantly lower costs for the healthcare system at 1 year ($36,000 less per patient); Shorter length of stay during their treatment (2.2 fewer days); and Fewer follow-up heart failure hospitalizations 1 year after treatment (80 percent less). Additionally, compared with asymptomatic severe AS, delaying treatment until the disease progressed resulted in a more than seven times higher rate of death within one year after aortic valve replacement (AVR). "We are dedicated to advancing robust evidence to help improve outcomes for patients with severe aortic stenosis," said Larry Wood, Edwards' corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical. "These latest findings underscore the importance of early referral to a Heart Valve Team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals." Along with prior data from the EARLY TAVR trial, these results reinforce the value of early referral and evaluation by a Heart Valve Team for all patients with severe AS. "We continue to believe that watchful waiting is not an effective strategy for the management of severe AS," said Philippe Genereux, M.D., director of the structural heart program at Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey. "The latest findings highlight the significant clinical and economic advantages of timely referral and treatment for severe AS patients." About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at and follow us on LinkedIn, Facebook, Instagram and YouTube. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as "may," "might," "believe," "will," "expect," "project," "estimate," "should," "anticipate," "plan," "goal," "continue," "seek," "intend," "optimistic," "aspire," "confident" and other forms of these words and include, but are not limited to, statements made by Mr. Wood and statements regarding expected benefits of prompt intervention before symptoms develop, patient benefits and outcomes, reduction in economic and resource burdens for the healthcare system and expectations and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards, Edwards Lifesciences, the stylized E logo, and EARLY TAVR are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners. View source version on Contacts Media Contact: Heather Bukant, 949-250-2753Investor Contact: Mark Wilterding, 949-250-6826 Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
22-05-2025
- Health
- Business Wire
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes
PARIS--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced new economic and clinical evidence on severe aortic stenosis (AS) presented as a late-breaking clinical trial at EuroPCR 2025, further contributing to the extensive body of research on this disease. The results of a new real-world study of more than 24,000 patients demonstrated that intervening on the disease before symptoms develop reduces the economic and resource burden on the healthcare system and improves patient outcomes. Prompt intervention for severe AS patients before symptoms developed resulted in: Significantly lower costs for the healthcare system at 1 year ($36,000 less per patient); Shorter length of stay during their treatment (2.2 fewer days); and Fewer follow-up heart failure hospitalizations 1 year after treatment (80 percent less). Additionally, compared with asymptomatic severe AS, delaying treatment until the disease progressed resulted in a more than seven times higher rate of death within one year after aortic valve replacement (AVR). 'We are dedicated to advancing robust evidence to help improve outcomes for patients with severe aortic stenosis,' said Larry Wood, Edwards' corporate vice president and group president, Transcatheter Aortic Valve Replacement and Surgical. 'These latest findings underscore the importance of early referral to a Heart Valve Team and timely care of patients with severe AS, reducing the economic and resource burden for hospitals.' Along with prior data from the EARLY TAVR trial, these results reinforce the value of early referral and evaluation by a Heart Valve Team for all patients with severe AS. 'We continue to believe that watchful waiting is not an effective strategy for the management of severe AS,' said Philippe Genereux, M.D., director of the structural heart program at Gagnon Cardiovascular Institute, Morristown Medical Center, Morristown, New Jersey. 'The latest findings highlight the significant clinical and economic advantages of timely referral and treatment for severe AS patients.' About Edwards Lifesciences Edwards Lifesciences is the leading global structural heart innovation company, driven by a passion to improve patient lives. Through breakthrough technologies, world-class evidence and partnerships with clinicians and healthcare stakeholders, our employees are inspired by our patient-focused culture to deliver life-changing innovations to those who need them most. Discover more at and follow us on LinkedIn, Facebook, Instagram and YouTube. This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. We intend the forward-looking statements contained in this release to be covered by the safe harbor provisions of such Acts. These forward-looking statements can sometimes be identified by the use of forward-looking words, such as 'may,' 'might,' 'believe,' 'will,' 'expect,' 'project,' 'estimate,' 'should,' 'anticipate,' 'plan,' 'goal,' 'continue,' 'seek,' 'intend,' 'optimistic,' 'aspire,' 'confident' and other forms of these words and include, but are not limited to, statements made by Mr. Wood and statements regarding expected benefits of prompt intervention before symptoms develop, patient benefits and outcomes, reduction in economic and resource burdens for the healthcare system and expectations and other statements that are not historical facts. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made, and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. Investors are cautioned not to unduly rely on such forward-looking statements. Forward-looking statements involve risks and uncertainties that could cause results to differ materially from those expressed or implied by the forward-looking statements based on a number of factors as detailed in the company's filings with the Securities and Exchange Commission. These filings, along with important safety information about our products, may be found at Edwards, Edwards Lifesciences, the stylized E logo, and EARLY TAVR are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.
